Table 1 The general characteristics of eligible studies in the meta-analysis.

From: Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy

Study	Year	Country	Ethnicity	Number of patients	Median age (year)	Clinical stage	Evaluation criterion	Outcomes	Genotyping methods	Arg194Trp genotype distribution			Arg399Gln genotype distribution			HR	QS
Study	Year	Country	Ethnicity	Number of patients	Median age (year)	Clinical stage	Evaluation criterion	Outcomes	Genotyping methods	Trp/Trp	Trp/Arg	Arg/Arg	Gln/Gln	Gln/Arg	Arg/Arg	HR	QS
Wang et al.,²⁹	2004	China	Asian	105	56	IIIB-IV	WHO	ORR	PCR-RFLP	3/11^a	19/18^a	11/43^a	2/8^a	9/33^a	22/31^a	NR	13
Wang et al.,²⁹	2004	China	Asian	105	(30–74)	IIIB-IV	WHO	ORR	PCR-RFLP	3/11^a	19/18^a	11/43^a	2/8^a	9/33^a	22/31^a	NR	13
Gurubhagavatula et al.,¹⁰	2004	USA	Caucasian	103	58	IIIA/B-IV	RECIST	OS/MST	PCR-RFLP	—	—	—	10^b	42^b	51^b	HR	19
Gurubhagavatula et al.,¹⁰	2004	USA	Caucasian	103	(32–77)	IIIA/B-IV	RECIST	OS/MST	PCR-RFLP	—	—	—	10^b	42^b	51^b	HR	19
Gao et al.,³⁰	2006	China	Asian	57	59	II-IV	WHO	ORR	PCR-RFLP	2/2^a	12/11^a	5/25^a	0/3^a	8/15^a	11/20^a	NR	12
Gao et al.,³⁰	2006	China	Asian	57	(38–77)	II-IV	WHO	ORR	PCR-RFLP	2/2^a	12/11^a	5/25^a	0/3^a	8/15^a	11/20^a	NR	12
Yuan et al.,³¹	2006	China	Asian	200	56	IIIB-IV	WHO	ORR	PCR-RFLP	10/13^a	38/46^a	24/69^a	—	—	—	NR	14
Yuan et al.,³¹	2006	China	Asian	200	(30–74)	IIIB-IV	WHO	ORR	PCR-RFLP	10/13^a	38/46^a	24/69^a	—	—	—	NR	14
Shi et al.,³²	2006	China	Asian	112	60	II-IV	WHO	ORR	PCR-RFLP	9/3^a	24/27^a	18/30^a	4/7^a	19/17^a	28/37^a	NR	13
Shi et al.,³²	2006	China	Asian	112	(22–81)	II-IV	WHO	ORR	PCR-RFLP	9/3^a	24/27^a	18/30^a	4/7^a	19/17^a	28/37^a	NR	13
Jin et al.,³³	2006	China	Asian	162	(28–75)	IIIB-IV	WHO	ORR	PCR-RFLP	10/14^a	35/25^a	27/51^a	—	—	—	NR	14
de las Penas R. et al.,³⁴	2006	Spain	Caucasian	135	62	IIIB-IV	RECIST	OS/MST	TaqMan	—	—	—	18^b	63^b	49^b	HR	20
de las Penas R. et al.,³⁴	2006	Spain	Caucasian	135	(31–81)	IIIB-IV	RECIST	OS/MST	TaqMan	—	—	—	18^b	63^b	49^b	HR	20
Wang et al. ,³⁵	2006	China	Asian	135	55	IIIB-IV	WHO	ORR/MST	PCR-RFLP	34/35^a^,^c		30/36^a	25/40^a^,^d		39/31^a	NR	16
Wang et al. ,³⁵	2006	China	Asian	135	(29–74)	IIIB-IV	WHO	ORR/MST	PCR-RFLP	34/35^a^,^c		30/36^a	25/40^a^,^d		39/31^a	NR	16
Song et al.,³⁶	2007	China	Asian	97	56	IIIB-IV	WHO	ORR	PCR-RFLP	3/8^a	19/22^a	8/37^a	1/4^a	11/29^a	18/34^a	NR	12
Song et al.,³⁶	2007	China	Asian	97	(30–68)	IIIB-IV	WHO	ORR	PCR-RFLP	3/8^a	19/22^a	8/37^a	1/4^a	11/29^a	18/34^a	NR	12
Giachino et al.³⁷	2007	Italy	Caucasian	248	62	IIIA/B-IV	RECIST	ORR/OS/MST	PCR-RFLP	—	—	—	12/17^a	18/82^a	31/88^a	HR	17
Giachino et al.³⁷	2007	Italy	Caucasian	248	(41–79)	IIIA/B-IV	RECIST	ORR/OS/MST	PCR-RFLP	—	—	—	12/17^a	18/82^a	31/88^a	HR	17
Song et al.,³⁸	2007	China	Asian	166	56	IIIB-IV	WHO	ORR	PCR-RFLP	4/12^a	34/32^a	14/70^a	—	—	—	NR	14
Song et al.,³⁸	2007	China	Asian	166	(30–68)	IIIB-IV	WHO	ORR	PCR-RFLP	4/12^a	34/32^a	14/70^a	—	—	—	NR	14
Chen et al., ³⁹	2007	China	Asian	64	55	Advanced	RECIST	ORR/PFS	TaqMan	—	—	—	0/2^a	20/40^a	2/0^a	NR	10
Chen et al., ³⁹	2007	China	Asian	64	(20–75)	Advanced	RECIST	ORR/PFS	TaqMan	—	—	—	0/2^a	20/40^a	2/0^a	NR	10
Liu et al.,⁴⁰	2008	China	Asian	53	61	I-IV	RECIST	OS/MST/TTP	TaqMan	—	—	—	8^b	18^b	27^b	HR	19
Liu et al.,⁴⁰	2008	China	Asian	53	(28–74)	I-IV	RECIST	OS/MST/TTP	TaqMan	—	—	—	8^b	18^b	27^b	HR	19
Fan et al.,⁴¹	2008	China	Asian	81	62.9	IIIB–IV	WHO	ORR	PCR-RFLP	—	—	—	16/20^a^,^d		13/32^a	NR	12
Fan et al.,⁴¹	2008	China	Asian	81	(55–80)	IIIB–IV	WHO	ORR	PCR-RFLP	—	—	—	16/20^a^,^d		13/32^a	NR	12
Qiu et al.,⁴²	2009	China	Asian	107	NR	III-IV	WHO	ORR	PCR-RFLP	7/6^a	27/23^a	14/30^a	—	—	—	NR	13
Sun et al.,⁴³	2009	China	Asian	87	59	IV	WHO	ORR	3D DNA microarray	5/6^a	18/19^a	8/31^a	1/3^a	8/22^a	14/39^a	NR	13
Sun et al.,⁴³	2009	China	Asian	87	(34–79)	IV	WHO	ORR	3D DNA microarray	5/6^a	18/19^a	8/31^a	1/3^a	8/22^a	14/39^a	NR	13
Hong et al., ⁴⁴	2009	China	Asian	164	61	III-IV	WHO	ORR	PCR-RFLP	7/11^a	31/42^a	19/54^a	3/10^a	28/53^a	26/44^a	NR	14
Hong et al., ⁴⁴	2009	China	Asian	164	(27–84)	III-IV	WHO	ORR	PCR-RFLP	7/11^a	31/42^a	19/54^a	3/10^a	28/53^a	26/44^a	NR	14
Kalikaki et al.,⁴⁵	2009	Greece	Caucasian	119	61	IIIA/B-IV	RECIST	ORR/OS/MST	PCR-RFLP	—	—	—	26/60^a,d		11/21^a	HR	17
Kalikaki et al.,⁴⁵	2009	Greece	Caucasian	119	(39–85)	IIIA/B-IV	RECIST	ORR/OS/MST	PCR-RFLP	—	—	—	26/60^a,d		11/21^a	HR	17
Yao et al.,⁴⁶	2009	China	Asian	108	61	IIIA/B-IV	WHO	ORR/OS/MST	PCR-RFLP	—	—	—	9/48^a, 60^b	12/28^a, 43^b	1/4^a, 5^b	HR	19
Yao et al.,⁴⁶	2009	China	Asian	108	(39–79)	IIIA/B-IV	WHO	ORR/OS/MST	PCR-RFLP	—	—	—	9/48^a, 60^b	12/28^a, 43^b	1/4^a, 5^b	HR	19
Qiu et al.,⁴⁷	2009	China	Asian	107	NR	III-IV	RECIST	ORR	PCR-RFLP	—	—	—	2/6^a	14/26^a	32/27^a	NR	13
Ding et al.,⁴⁸	2010	China	Asian	54	60	IIIB-IV	WHO	ORR	DNA Sequencing	4/3^a	9/10^a	12/16^a	3/10^a	4/6^a	18/13^a	NR	13
Ding et al.,⁴⁸	2010	China	Asian	54	(40–85)	IIIB-IV	WHO	ORR	DNA Sequencing	4/3^a	9/10^a	12/16^a	3/10^a	4/6^a	18/13^a	NR	13
Qian et al.,⁴⁹	2010	China	Asian	107	NR	IIIB-IV	WHO	ORR	PCR-RFLP	—	—	—	2/6^a	14/26^a	32/27^a	NR	13
Yuan et al.,⁶	2010	China	Asian	199	56	IIIA-IV	WHO	OS/PFS/MST	PCR-RFLP	23^b	83^b	93^b	20^b	74^b	105^b	HR	23
Yuan et al.,⁶	2010	China	Asian	199	(29–74)	IIIA-IV	WHO	OS/PFS/MST	PCR-RFLP	23^b	83^b	93^b	20^b	74^b	105^b	HR	23
Ying et al.,⁵⁰	2010	China	Asian	80	30–78	IIIB-IV	WHO	ORR	PCR-RFLP	5/7^a	17/12^a	13/26^a	—	—	—	NR	12
Cheng et al.^51,52	2011	China	Asian	120	58	Advanced	WHO	ORR/MST	DNA microarray	—	—	—	5/14^a	9/44^a	21/27^a	KM	15
Cheng et al.^51,52	2011	China	Asian	120	(34–77)	Advanced	WHO	ORR/MST	DNA microarray	—	—	—	5/14^a	9/44^a	21/27^a	KM	15
Han et al.,⁵³	2011	Korea	Asian	158	57	IIIB-IV	NR	OS/PFS	TaqMan	—	—	—	8^b	63^b	87^b	HR	12
Han et al.,⁵³	2011	Korea	Asian	158	(19–74)	IIIB-IV	NR	OS/PFS	TaqMan	—	—	—	8^b	63^b	87^b	HR	12
Zhou et al.,⁵⁴	2011	China	Asian	111	57	IV	RECIST	ORR/TTP	DNA Sequencing	—	—	—	6/34^a^,^d		29/42^a	NR	14
Zhou et al.,⁵⁴	2011	China	Asian	111	(42–71)	IV	RECIST	ORR/TTP	DNA Sequencing	—	—	—	6/34^a^,^d		29/42^a	NR	14
Zhou et al., ⁵⁵	2011	China	Asian	94	57	IIIB–IV	RECIST	ORR/TTP	DNA Sequencing	—	—	—	11/31^a^,^d		19/33^a	KM	14
Zhou et al., ⁵⁵	2011	China	Asian	94	(42–71)	IIIB–IV	RECIST	ORR/TTP	DNA Sequencing	—	—	—	11/31^a^,^d		19/33^a	KM	14
Han et al.,⁵⁶	2011	China	Asian	91	56	IV	RECIST	ORR/TTP	DNA Sequencing	—	—	—	8/33^a^,^d		20/30^a	NR	10
Xu et al.,⁵⁷	2011	China	Asian	130	62	IIIB-IV	RECIST	ORR	PCR-RFLP	18/18^a	14/26^a	12/42^a	0/10^a	14/40^a	30/36^a	NR	13
Xu et al.,⁵⁷	2011	China	Asian	130	(28–83)	IIIB-IV	RECIST	ORR	PCR-RFLP	18/18^a	14/26^a	12/42^a	0/10^a	14/40^a	30/36^a	NR	13
Hong et al.,⁵⁸	2011	China	Asian	262	NR	I-IV	NR	OS/MST	TaqMan	—	—	—	20^b	77^b	165^b	HR	13
Joerger et al.,⁵⁹	2012	Switzerland	Caucasian	131	59.7	IIIB–IV	RECIST	ORR/OS/PFS/MST	DNA Sequencing	—	—	—	5/12^a	18/45^a	17/34^a	HR	23
Joerger et al.,⁵⁹	2012	Switzerland	Caucasian	131	(37–79)	IIIB–IV	RECIST	ORR/OS/PFS/MST	DNA Sequencing	—	—	—	5/12^a	18/45^a	17/34^a	HR	23
Li et al.,⁶⁰	2012	China	Asian	89	59.08	III–IV	RECIST	ORR	DNA Sequencing	—	—	—	6/39^a^,^d		20/24^a	NR	13
Li et al.,⁶⁰	2012	China	Asian	89	(21–84)	III–IV	RECIST	ORR	DNA Sequencing	—	—	—	6/39^a^,^d		20/24^a	NR	13
Xu et al.,⁶¹	2012	China	Asian	149	62	IIIB-IV	RECIST	ORR	PCR-RFLP	9/9^a	24/38^a	16/53^a	—	—	—	NR	13
Xu et al.,⁶¹	2012	China	Asian	149	(28–83)	IIIB-IV	RECIST	ORR	PCR-RFLP	9/9^a	24/38^a	16/53^a	—	—	—	NR	13
Zha et al.,⁶²	2012	China	Asian	52	63	IIIA-IIIB	WHO	ORR	PCR-LDR	—	—	—	13/15^a^,^d		13/11^a	NR	12
Zha et al.,⁶²	2012	China	Asian	52	(45–75)	IIIA-IIIB	WHO	ORR	PCR-LDR	—	—	—	13/15^a^,^d		13/11^a	NR	12
Ke et al.,⁶³	2012	China	Asian	460	55	I-IV	NR	ORR/OS	PCR-CTPP	44/19^a	45/52^a	104/196^a	36/15^a	85/92^a	72/160^a	HR	14
Ke et al.,⁶³	2012	China	Asian	460	(32–79)	I-IV	NR	ORR/OS	PCR-CTPP	44/19^a	45/52^a	104/196^a	36/15^a	85/92^a	72/160^a	HR	14
Liao et al.,⁶⁴	2012	China	Asian	62	57	IIIB-IV	NR	ORR/OS/PFS/MST	SNPstream UHT	—	—	—	1/4	9/22	9/17	HR	19
Liao et al.,⁶⁴	2012	China	Asian	62	(36–78)	IIIB-IV	NR	ORR/OS/PFS/MST	SNPstream UHT	—	—	—	1/4	9/22	9/17	HR	19
Liao et al.,⁶⁴	2012	China	Asian	45	63	IIIB-IV	NR	OS/PFS/MST	SNPstream UHT	—	—	—	2^b	24^b	19^b	HR	16
Liao et al.,⁶⁴	2012	China	Asian	45	(43–83)	IIIB-IV	NR	OS/PFS/MST	SNPstream UHT	—	—	—	2^b	24^b	19^b	HR	16
Liu et al.,⁶⁵	2013	China	Asian	62	58	Advanced	RECIST	ORR	TaqMan	—	—	—	4/23^a		15/20^a	NR	10
Liu et al.,⁶⁵	2013	China	Asian	62	(37–72)	Advanced	RECIST	ORR	TaqMan	—	—	—	4/23^a		15/20^a	NR	10
Li et al.,⁶⁶	2013	China	Asian	83	63.07	IIIA-IV	WHO	ORR	PCR-RFLP	—	—	—	1/5^a	3/25^a	21/28^a	NR	9
Yang et al.,⁶⁷	2013	China	Asian	54	56	IIIB–IV	RECIST	ORR/MST	PCR-RFLP	3/1^a	10/4^a	13/23^a	—	—	—	NR	15
Yang et al.,⁶⁷	2013	China	Asian	54	(30–73)	IIIB–IV	RECIST	ORR/MST	PCR-RFLP	3/1^a	10/4^a	13/23^a	—	—	—	NR	15
Sheng et al.,⁶⁸	2013	China	Asian	62	58	Advanced	RECIST	ORR	TaqMan	—	—	—	1/4^a	3/19^a	15/20^a	NR	10
Sheng et al.,⁶⁸	2013	China	Asian	62	(37–72)	Advanced	RECIST	ORR	TaqMan	—	—	—	1/4^a	3/19^a	15/20^a	NR	10
Lee et al.,⁶⁹	2013	Korea	Asian	382	NR	III-IV	NR	ORR/OS/MST	Sequenome MS-based genotyping assay	—	—	—	5/16^a	64/75^a	110/100^a	HR	18
Liu et al.,⁷⁰	2013	China	Asian	200	56	IIIB-IV	NR	ORR	PCR-RFLP	10/13^a	38/46^a	24/69^a	—	—	—	NR	11
Liu et al.,⁷⁰	2013	China	Asian	200	(30–74)	IIIB-IV	NR	ORR	PCR-RFLP	10/13^a	38/46^a	24/69^a	—	—	—	NR	11
Zhao et al.,⁷¹	2013	China	Asian	147	60	IIIB-IV	RECIST	ORR/OS/PFS/MST	TaqMan	1/6^a	20/35^a	32/51^a	8/5^a	24/31^a	21/56^a	HR	23
Zhao et al.,⁷¹	2013	China	Asian	147	(32–82)	IIIB-IV	RECIST	ORR/OS/PFS/MST	TaqMan	1/6^a	20/35^a	32/51^a	8/5^a	24/31^a	21/56^a	HR	23
Deng et al.,⁷²	2013	China	Asian	97	57	IIIB-IV	RECIST	ORR/PFS	PCR-RFLP and DNA Sequencing	—	—	—	9/35^a^,^d		16/37^a	NR	15
Deng et al.,⁷²	2013	China	Asian	97	(31–79)	IIIB-IV	RECIST	ORR/PFS	PCR-RFLP and DNA Sequencing	—	—	—	9/35^a^,^d		16/37^a	NR	15
Zhou et al., ⁷³	2014	China	Asian	204	61	NR	RECIST	ORR/OS/MST	MALDI-TOF-MS	—	—	—	23/78^a^,^d		38/65^a	KM	16
Zhou et al., ⁷³	2014	China	Asian	204	(45–75)	NR	RECIST	ORR/OS/MST	MALDI-TOF-MS	—	—	—	23/78^a^,^d		38/65^a	KM	16
Peng et al.,⁷	2014	China	Asian	235	58	IIIA-IV	RECIST	ORR/OS/PFS/MST	PCR-CTTP	—	—	—	3/6^a	41/74^a	40/71^a	HR	20
Peng et al.,⁷	2014	China	Asian	235	(29–84)	IIIA-IV	RECIST	ORR/OS/PFS/MST	PCR-CTTP	—	—	—	3/6^a	41/74^a	40/71^a	HR	20
Zhang et al.,⁷⁴	2014	China	Asian	375	60.9	IIIA-IV	NR	ORR/OS/PFS/MST	MassARRAY	23/41^a	44/90^a	60/118^a	24/29^a	54/94^a	49/125^a	HR	21
Jin et al.,⁷⁵	2014	China	Asian	378	62.4	I-IV	NR	ORR/OS/DFS	PCR-RFLP	25/29^a	48/71^a	71/134^a	28/19^a	64/96^a	52/119^a	HR	14
Jin et al.,⁷⁵	2014	China	Asian	378	(36–78)	I-IV	NR	ORR/OS/DFS	PCR-RFLP	25/29^a	48/71^a	71/134^a	28/19^a	64/96^a	52/119^a	HR	14
Sullivan et al.,⁷⁶	2014	Spain	Caucasian	161	63.7	IIIA-IV	RECIST	ORR/OS/PFS	TaqMan	11/8^a^,^c	78/64^a	13/14^a	39/33^a		37/25^a	NR	15
Sullivan et al.,⁷⁶	2014	Spain	Caucasian	161	(36–85)	IIIA-IV	RECIST	ORR/OS/PFS	TaqMan	11/8^a^,^c	78/64^a	13/14^a	39/33^a		37/25^a	NR	15
Liu et al.,⁷⁷	2014	China	Asian	82	59.85	Advanced	NR	ORR	PCR-RFLP	4/5^a	16/19^a	11/27^a	2/6^a	14/23^a	13/24^a	NR	6
Liu et al.,⁷⁷	2014	China	Asian	82	(29–78)	Advanced	NR	ORR	PCR-RFLP	4/5^a	16/19^a	11/27^a	2/6^a	14/23^a	13/24^a	NR	6
Kalikaki et al.,⁷⁸	2015	Greece	Caucasian	107	60.0	IIIB-IV	RECIST	OS/PFS/MST	PCR-RFLP	—	—	—	23/44^a^,^d		16/22^a	HR	22
Kalikaki et al.,⁷⁸	2015	Greece	Caucasian	107	(37–78)	IIIB-IV	RECIST	OS/PFS/MST	PCR-RFLP	—	—	—	23/44^a^,^d		16/22^a	HR	22

Note: NR: not reported; QS, quality score; HR: hazard ratio; ORR: objective response rate; OS, overall survival (months); KM, Kaplan-Meier curve; DFS, disease-free survival (months); PFS, progression-free survival (months); MST, median survival time (months); TTP, time to progression (months); 3D, 3-dimensional; PCR, polymerase chain reaction; PCR-RFLP, PCR-restriction fragment length polymorphism; RECIST, Response Evaluation Criteria in Solid Tumors; WHO, World Health Organization; MALDI-TOF-MS, matrix-assisted laser desorption/ionization time of light mass spectrometry; PCR-LDR, PCR-ligase detection reaction; PCR-CTPP, duplex PCR with the confronting-two-pair primer; Sequenome MS-based genotyping assay, sequenome mass spectrometry-based genotyping assay; SNPstream UHT, SNPstream ultra high throughput; PCR-CTTP, PCR with confronting two-pair primers.
^aNumber of patients for ORR; in front of oblique line is good responder (complete response (CR) + partial response (PR)) and behind oblique line is poor responder (stable disease (SD) + progressive disease (PD)).
^bNumber of patients for OS.
^cNumber of patients for Trp/Trp and Trp/Arg genotypes.
^dNumber of patients for Gln/Gln and Gln/Arg genotypes.

Back to article page

Table 1 The general characteristics of eligible studies in the meta-analysis.

Search

Quick links